ICAM3 and cancer: In the cancer cell in vitro studies, Shen W et al. found that Lifitegrast is also more able to reduce the binding of ICAM3 and LFA-1, inhibit the migration and movement of cancer cells caused by the binding of ICAM3/LFA-1, and then inhibit the cancer metastasis and cancer progression, which provides a new basis for the treatment of metastatic cancers 34.